Ignet

Gene Information

Gene symbol: VEGFB

Gene name: vascular endothelial growth factor B

HGNC ID: 12681

Synonyms: VEGFL

Related Genes

#	Gene Symbol	Number of hits
1	ANGPT1	1 hits
2	ANGPT2	1 hits
3	ANGPT4	1 hits
4	ANGPTL1	1 hits
5	FIGF	1 hits
6	FLT1	1 hits
7	INS	1 hits
8	KDR	1 hits
9	NRP1	1 hits
10	PDGFA	1 hits
11	PDGFB	1 hits
12	PGF	1 hits
13	RBL2	1 hits
14	THBS1	1 hits
15	VEGFA	1 hits
16	VEGFC	1 hits

Related Sentences

#	PMID	Sentence
1	15127326	Differential regulation of ANG2 and VEGF-A in human granulosa lutein cells by choriogonadotropin.
2	15127326	In this study we investigated by RT PCR if the growth factors PGF, PDGF-A, PDGF-B, VEGF-A, VEGF-B, VEGF-C, VEGF-D, ANG1, ANG2, ANG3 and ANG4 are expressed in granulosa cells.
3	15127326	We show the expression of VEGF-A, VEGF-B, PDGF-A, ANG1 and ANG2 in granulosa cells.
4	15127326	Using RT-PCR and Real-Time PCR we demonstrate that angiopoietin 2 is downregulated in human granulosa cells in vitro after choriogonadotropin treatment whereas the expression of angiopoietin 1 is not significantly altered.
5	15127326	In total these findings suggests that in granulosa cells the mRNA of various growth factors is detectable by RT-PCR and that VEGF-A and ANG2 is regulated by the gonadotropic hormone choriogonadotropin.
6	15127326	Differential regulation of ANG2 and VEGF-A in human granulosa lutein cells by choriogonadotropin.
7	15127326	In this study we investigated by RT PCR if the growth factors PGF, PDGF-A, PDGF-B, VEGF-A, VEGF-B, VEGF-C, VEGF-D, ANG1, ANG2, ANG3 and ANG4 are expressed in granulosa cells.
8	15127326	We show the expression of VEGF-A, VEGF-B, PDGF-A, ANG1 and ANG2 in granulosa cells.
9	15127326	Using RT-PCR and Real-Time PCR we demonstrate that angiopoietin 2 is downregulated in human granulosa cells in vitro after choriogonadotropin treatment whereas the expression of angiopoietin 1 is not significantly altered.
10	15127326	In total these findings suggests that in granulosa cells the mRNA of various growth factors is detectable by RT-PCR and that VEGF-A and ANG2 is regulated by the gonadotropic hormone choriogonadotropin.
11	16816123	For example, levels of proangiogenic VEGF-A, VEGF-B, neuropilin-1, VEGFR-1, and VEGFR-2 were reduced and the levels of antiangiogenic thrombospondin-1 and retinoblastoma like-2 were increased.
12	23023133	Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.
13	23023133	Here we show that decreased VEGF-B signalling in rodent models of type 2 diabetes restores insulin sensitivity and improves glucose tolerance.
14	23023133	The potential use of VEGF-B neutralization in type 2 diabetes was further elucidated in rats fed a high-fat diet, in which it normalized insulin sensitivity and increased glucose uptake in skeletal muscle and heart.
15	23023133	We propose VEGF-B antagonism as a novel pharmacological approach for type 2 diabetes, targeting the lipid-transport properties of the endothelium to improve muscle insulin sensitivity and glucose disposal.
16	23023133	Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.
17	23023133	Here we show that decreased VEGF-B signalling in rodent models of type 2 diabetes restores insulin sensitivity and improves glucose tolerance.
18	23023133	The potential use of VEGF-B neutralization in type 2 diabetes was further elucidated in rats fed a high-fat diet, in which it normalized insulin sensitivity and increased glucose uptake in skeletal muscle and heart.
19	23023133	We propose VEGF-B antagonism as a novel pharmacological approach for type 2 diabetes, targeting the lipid-transport properties of the endothelium to improve muscle insulin sensitivity and glucose disposal.
20	23023133	Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.
21	23023133	Here we show that decreased VEGF-B signalling in rodent models of type 2 diabetes restores insulin sensitivity and improves glucose tolerance.
22	23023133	The potential use of VEGF-B neutralization in type 2 diabetes was further elucidated in rats fed a high-fat diet, in which it normalized insulin sensitivity and increased glucose uptake in skeletal muscle and heart.
23	23023133	We propose VEGF-B antagonism as a novel pharmacological approach for type 2 diabetes, targeting the lipid-transport properties of the endothelium to improve muscle insulin sensitivity and glucose disposal.
24	23023133	Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.
25	23023133	Here we show that decreased VEGF-B signalling in rodent models of type 2 diabetes restores insulin sensitivity and improves glucose tolerance.
26	23023133	The potential use of VEGF-B neutralization in type 2 diabetes was further elucidated in rats fed a high-fat diet, in which it normalized insulin sensitivity and increased glucose uptake in skeletal muscle and heart.
27	23023133	We propose VEGF-B antagonism as a novel pharmacological approach for type 2 diabetes, targeting the lipid-transport properties of the endothelium to improve muscle insulin sensitivity and glucose disposal.